Your browser doesn't support javascript.
A European pharmacotherapeutic agent roflumilast exploring integrated preclinical and clinical evidence for SARS CoV-2 mediated inflammation to organ damage.
Singh, Yogendra; Fuloria, Neeraj Kumar; Fuloria, Shivkanya; Subramaniyan, Vetriselvan; Almalki, Waleed Hassan; Al-Abbasi, Fahad A; Kazmi, Imran; Rajput, Sobhit Singh; Joshi, Nirmal; Gupta, Gaurav.
  • Singh Y; Department of Pharmacology, Maharishi Arvind College of Pharmacy, Jaipur, India.
  • Fuloria NK; Faculty of Pharmacy, AIMST University, Bedong, Malaysia.
  • Fuloria S; Faculty of Pharmacy, AIMST University, Bedong, Malaysia.
  • Subramaniyan V; Faculty of Medicine, Bioscience and Nursing, MAHSA University, Jenjarom, Selangor, Malaysia.
  • Almalki WH; Department of Pharmacology, College of Pharmacy, Umm Al-Qura University, Makkah, Saudi Arabia.
  • Al-Abbasi FA; Department of Biochemistry, Faculty of Science, King Abdulaziz University, Jeddah, Saudi Arabia.
  • Kazmi I; Department of Biochemistry, Faculty of Science, King Abdulaziz University, Jeddah, Saudi Arabia.
  • Rajput SS; Aligarh College of Pharmacy, Aligarh, India.
  • Joshi N; Amrapali Institute of Pharmacy and Sciences, Haldwani, India.
  • Gupta G; Department of Pharmacology, School of Pharmacy, Suresh Gyan Vihar University, Jaipur, India.
Br J Clin Pharmacol ; 88(8): 3562-3565, 2022 08.
Article Dans Anglais | MEDLINE | ID: covidwho-1764882
ABSTRACT
COVID-19 has spread globally, affecting almost 160 million individuals. Elderly and pre-existing patients (such as diabetes, heart disease and asthma) seem more susceptible to severe illness with COVID-19. Roflumilast was licensed for usage in the European Union in July 2010 as a phosphodiesterase-4 (PDE4) inhibitor. Under preclinical studies, roflumilast has been shown to decrease bleomycin-induced lung fibrosis, lung hydroxyproline and right heart thickening. The current study reviewed existing data that the PDE-4 inhibitor, a roflumilast, protects renal tissues and other major organ systems after COVID-19 infection by decreasing immune cell infiltration. These immune-balancing effects of roflumilast were related to a decrease in oxidative and inflammatory burden, caspase-3 suppression and increased protein kinase A (PKA)/cyclic A.M.P. (cAMP) levels in renal and other organ tissue.
Sujets)
Mots clés

Texte intégral: Disponible Collection: Bases de données internationales Base de données: MEDLINE Sujet Principal: Inhibiteurs de la phosphodiestérase-4 / Type d'étude: Étude pronostique Limites du sujet: Adulte très âgé / Humains langue: Anglais Revue: Br J Clin Pharmacol Année: 2022 Type de document: Article Pays d'affiliation: Bcp.15328

Documents relatifs à ce sujet

MEDLINE

...
LILACS

LIS


Texte intégral: Disponible Collection: Bases de données internationales Base de données: MEDLINE Sujet Principal: Inhibiteurs de la phosphodiestérase-4 / Type d'étude: Étude pronostique Limites du sujet: Adulte très âgé / Humains langue: Anglais Revue: Br J Clin Pharmacol Année: 2022 Type de document: Article Pays d'affiliation: Bcp.15328